Diego Gianolio

Diego Gianolio, Ph.D. has extensive work experience in the pharmaceutical industry, specializing in clinical science and development. Diego is currently the Director of Clinical Science in Cancer Metabolism at Servier Pharmaceuticals, where they oversee the clinical trial for ivosidenib and azacitidine in newly diagnosed Acute Myeloid Leukemia (AML). Diego has successfully led regulatory submissions for AML and is currently leading a phase 3 clinical trial in sarcoma. Prior to this, Diego worked as the Director of Clinical Science in Hematology and IDH mutations at Agios Pharmaceuticals, where they were responsible for the strategic, clinical, translational, and operational aspects of clinical development programs. Diego also built strong relationships with key opinion leaders and external stakeholders. Before that, Diego held positions at Sanofi, where they designed and implemented clinical studies for adult and pediatric cancers, supported medical affairs activities, and developed scientific and medical communication for global meetings. Diego has experience in overseeing Phase 3 and post-marketing clinical trials and conducting research and development projects in various cancer areas, including breast cancer and sarcoma. Diego also has a background in bio-organic chemistry and biologics, having served as a Post Doctoral Fellow at Boston College, where they conducted research on nucleobase synthesis and DNA modifications.

Diego Gianolio, Ph.D., obtained their Doctor of Philosophy - PhD degree in Organic Chemistry (full honors) from Università degli Studi di Parma, where they studied from 1991 to 1996.